JP2024504777A5 - - Google Patents

Info

Publication number
JP2024504777A5
JP2024504777A5 JP2023545809A JP2023545809A JP2024504777A5 JP 2024504777 A5 JP2024504777 A5 JP 2024504777A5 JP 2023545809 A JP2023545809 A JP 2023545809A JP 2023545809 A JP2023545809 A JP 2023545809A JP 2024504777 A5 JP2024504777 A5 JP 2024504777A5
Authority
JP
Japan
Prior art keywords
fusion protein
subunit
nanocage
item
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050122 external-priority patent/WO2022160057A1/en
Publication of JP2024504777A publication Critical patent/JP2024504777A/ja
Publication of JP2024504777A5 publication Critical patent/JP2024504777A5/ja
Pending legal-status Critical Current

Links

JP2023545809A 2021-01-28 2022-01-28 Multabody構築物、組成物および方法 Pending JP2024504777A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142704P 2021-01-28 2021-01-28
US63/142,704 2021-01-28
PCT/CA2022/050122 WO2022160057A1 (en) 2021-01-28 2022-01-28 Multabody constructs, compositions, and methods

Publications (2)

Publication Number Publication Date
JP2024504777A JP2024504777A (ja) 2024-02-01
JP2024504777A5 true JP2024504777A5 (cg-RX-API-DMAC7.html) 2025-02-04

Family

ID=82652697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545809A Pending JP2024504777A (ja) 2021-01-28 2022-01-28 Multabody構築物、組成物および方法

Country Status (9)

Country Link
US (1) US20240317842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284840A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504777A (cg-RX-API-DMAC7.html)
KR (1) KR20230136166A (cg-RX-API-DMAC7.html)
CN (1) CN117157328A (cg-RX-API-DMAC7.html)
AU (1) AU2022212978A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208446A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023008912A (cg-RX-API-DMAC7.html)
WO (1) WO2022160057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4370558A4 (en) * 2021-07-12 2025-09-10 Hospital For Sick Children OPTIMIZED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS
MX2024003140A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Construcciones, composiciones y metodos de multabody optimizados.
US20250002564A1 (en) * 2021-10-16 2025-01-02 The Hospital For Sick Children Modified multabody constructs, compositions, and methods
EP4416189A4 (en) * 2021-10-16 2025-08-27 Hospital For Sick Children MODIFIED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS TARGETING SARS-CoV-2
EP4634238A1 (en) * 2022-12-18 2025-10-22 Radiant Biotherapeutics Inc. Multivalent hematopoietic cell engagers or activators
CN120771308B (zh) * 2025-09-04 2025-12-12 中山大学 一种具有缓释效应的蛋白笼纳米药物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048288A2 (en) * 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
BR112017014219A2 (en) * 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
CA3071922A1 (en) * 2017-08-04 2019-02-07 The Governing Council Of The University Of Toronto Nanoparticle platform for antibody and vaccine delivery
CN113395978A (zh) * 2018-07-11 2021-09-14 动量制药公司 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
AU2020315598B2 (en) * 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3149320A1 (en) * 2019-08-01 2021-02-04 The Hospital For Sick Children Multi-valent and multi-specific nanoparticle platforms and methods
MX2023004023A (es) * 2020-10-09 2023-07-07 Hospital For Sick Children Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados.

Similar Documents

Publication Publication Date Title
JP7328267B2 (ja) Hiv感染症の予防または処置のための三重特異性および/または三価結合タンパク質
US20230357401A1 (en) Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
JP6104121B2 (ja) 操作されたヘテロ二量体タンパク質ドメイン
JP6772157B2 (ja) インフルエンザヘマグルチニンに対する結合分子及びその使用
JP2019519527A (ja) 操作されたFcコンストラクトに関する組成物及び方法
RU2015145719A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2023544211A5 (cg-RX-API-DMAC7.html)
JP2022543070A5 (cg-RX-API-DMAC7.html)
JP2017523814A5 (cg-RX-API-DMAC7.html)
CA3232349A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
JP2019502694A (ja) 二特異性抗体基幹
CN110234355A (zh) 单体人IgG1 Fc和双特异性抗体
JP7676316B2 (ja) Hiv感染症の処置のためのクロスオーバー二重可変ドメイン(codv)フォーマットを使用した三重特異性および/または三価結合性タンパク質
US10344078B2 (en) Type III secretion system targeting molecules
JP2024504777A (ja) Multabody構築物、組成物および方法
JP2021512159A5 (cg-RX-API-DMAC7.html)
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
BR112019013955A2 (pt) Composições e métodos relacionados a construtos de fc manipulados
JP2024541905A (ja) 人工操作Fcバリアント
JP2023550191A5 (cg-RX-API-DMAC7.html)
US20220144956A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
US20130189247A1 (en) Multimeric Proteins Comprising Immunoglobulin Constant Domains
Wang et al. New directions for half-life extension of protein therapeutics: the rise of antibody Fc domains and fragments
BR112021000393A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado
JP2024525691A5 (cg-RX-API-DMAC7.html)